Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Anti fungal terbinafine launched in Europe: Actavis

Terbinafine, a new antifungal-medicine, has been launched in 15 European countries, the drug maker Actavis said in a news release.



13 September,2005: The product, whose patent recently expired, was shipped to clients at patent expiry. The first orders were around 10 million tablets and the company estimates that Terbinafine will become the Groupís highest selling ant ifungal - medicine. The product is still not expected to reach the Groupís ten highest selling products.

Terbinafine is a well known medicine, mainly used in the treatment of fungal infection in skin and nails. Terbinafine from Actavis is distributed in tablets in two strengths, but the company is also developing a Terbinafine cream. The product was originally launched in the UK in 1990, but its patent expired recently. 

The product is manufactured and packaged by Actavis in Malta, and Actavisí subsidiary Medis will handle the sale of the product in Europe under customer label, but Actavis Nordic will distribute the product in own-label in the Nordic countries. The product has been available in Iceland for a few years.

Founded in 1956, the Actavis Group now operates across five continents and has its headquarters in Iceland. Principal markets include Turkey, Germany, Bulgaria, Serbia, Russia and recently the US with the acquisition of Amide. It has a total workforce of around 7,000.

Actavis has modern manufacturing facilities in Bulgaria, Malta, Turkey, the US and Iceland that are EU-GMP (Good Manufacturing Practice) approved. The manufacturing facility in the US is FDA approved. Additional manufacturing in Serbia currently services domestic and other markets for own-label products outside the EU.



   Pharma Home

Chinese herbal products could be dangerous: UK 

Knock, knock! It's bird flu at the door

Spider anti-venom to be stocked in UAE hospital 

US may ban animal protein in cattle feed to safeguard against mad cow 

Dr Reddy's nizatidine generic gets FDA nod

Late-onset Pompe disease drug goes on trial

First biologic to treat ulcerative colitis gets US FDA okay

Diverticulitis orally dissolving pill from KV Pharma's  hits the market

Impax delisted from Nasdaq

US FDA okays Lupin's cephalexin

Hepatitis C combo therapy to get priority review in Japan

Lung cancer vaccine trials promising: Introgen

Sugar-free pill Actiq for cancer pain

39 drug firms sued over price rigging in California

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimerís disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally shortí kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takedaís drug combo for type 2 diabetes

Novartisí drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shireís ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies


Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us